---
title: "Neuropsychiatric drug developer Seaport files for U.S. IPO"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282423490.md"
description: "Seaport Therapeutics (SPTX), a biotech firm focused on neuropsychiatric diseases, has filed for an IPO in the U.S. to list on Nasdaq under the symbol \"SPTX.\" Founded by Daphne Zohar in 2024, the company plans to use IPO proceeds for R&D, particularly for its lead asset, GlyphAllo, currently in a Phase 2 trial for major depressive disorder. Seaport has not yet turned a profit, with a 2025 net loss of $74.9M and an accumulated deficit of $114.1M as of Dec. 31, 2025."
datetime: "2026-04-11T17:32:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282423490.md)
  - [en](https://longbridge.com/en/news/282423490.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282423490.md)
generator: "portal-rs"
---

# Neuropsychiatric drug developer Seaport files for U.S. IPO


### Related Stocks

- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SEELQ.US](https://longbridge.com/en/quote/SEELQ.US.md)
- [SEEL.US](https://longbridge.com/en/quote/SEEL.US.md)

## Related News & Research

- [LIVE MARKETS-BofA clients flock to tech stocks](https://longbridge.com/en/news/296383193.md)
- [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md)
- [Biotech Stocks Facing FDA Decision In September 2026](https://longbridge.com/en/news/297065559.md)
- [EverGen Infrastructure Reports Q2 2026 Results | EVGIF Stock News](https://longbridge.com/en/news/297122882.md)
- [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**